Medexus Pharmaceuticals Inc. (TSX:MDP)
Canada · Delayed Price · Currency is CAD 4.960
-0.100 (-1.98%)
Aug 10, 2026, 3:59 PM EST
Medexus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 103.3 | 99.33 | 108.33 | 113.05 | 108.1 | 76.7 | |
Revenue Growth | -2.23% | -8.31% | -4.18% | 4.59% | 40.93% | -3.72% |
Cost of Revenue | 37.33 | 35.48 | 44.82 | 47.99 | 42.33 | 33.03 |
Gross Profit | 65.97 | 63.86 | 63.51 | 65.07 | 65.77 | 43.67 |
Selling, General & Admin | 46.71 | 45.89 | 43.18 | 44.87 | 48.25 | 44.03 |
Research & Development | 2.44 | 2.4 | 1.23 | 1.61 | 2.94 | 5.87 |
Amortization of Goodwill & Intangibles | 9.43 | 9.45 | 6.93 | 5.56 | 5.73 | 5.75 |
Operating Expenses | 58.87 | 58.02 | 51.59 | 52.28 | 57.28 | 56.05 |
Operating Income | 7.1 | 5.84 | 11.92 | 12.79 | 8.49 | -12.38 |
Interest Expense | -5.05 | -5.2 | -8.2 | -13.36 | -13.61 | -12.22 |
Currency Exchange Gain (Loss) | 0.25 | 0.25 | -1.07 | - | -1.69 | -0.15 |
Other Non Operating Income (Expenses) | -1.53 | - | - | 2.68 | 2.64 | 23.55 |
EBT Excluding Unusual Items | 0.77 | 0.88 | 2.66 | 2.1 | -4.17 | -1.2 |
Merger & Restructuring Charges | -0.7 | -0.7 | -0.9 | -1.11 | -0.88 | -0.87 |
Gain (Loss) on Sale of Assets | 0.41 | 0.41 | - | - | - | - |
Asset Writedown | - | - | -2.8 | -0.89 | - | -1.75 |
Other Unusual Items | -2.86 | -2.86 | 2.48 | - | - | - |
Pretax Income | -2.39 | -2.27 | 1.44 | 0.11 | -5.04 | -3.82 |
Income Tax Expense | -0.02 | 0.12 | -0.81 | 0.32 | -6.26 | -0.94 |
Net Income | -2.37 | -2.39 | 2.25 | -0.21 | 1.22 | -2.88 |
Net Income to Common | -2.37 | -2.39 | 2.25 | -0.21 | 1.22 | -2.88 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 32 | 32 | 26 | 22 | 20 | 19 |
Shares Outstanding (Diluted) | 32 | 32 | 27 | 22 | 21 | 20 |
Shares Change | 13.18% | 21.91% | 18.76% | 8.76% | 3.36% | 30.65% |
EPS (Basic) | -0.07 | -0.07 | 0.09 | -0.01 | 0.06 | -0.15 |
EPS (Diluted) | -0.07 | -0.07 | 0.08 | -0.01 | 0.06 | -0.15 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | 14.18 | 18.72 | 23.85 | 18.66 | -1.51 | -1.28 |
Free Cash Flow Per Share | 0.44 | 0.58 | 0.90 | 0.84 | -0.07 | -0.06 |
Gross Margin | 63.86% | 64.29% | 58.62% | 57.56% | 60.84% | 56.94% |
Operating Margin | 6.87% | 5.87% | 11.00% | 11.31% | 7.85% | -16.13% |
Profit Margin | -2.29% | -2.41% | 2.07% | -0.19% | 1.13% | -3.75% |
Free Cash Flow Margin | 13.72% | 18.85% | 22.02% | 16.51% | -1.39% | -1.67% |
EBITDA | 16.64 | 15.39 | 18.94 | 18.44 | 14.37 | -6.46 |
EBITDA Margin | 16.11% | 15.50% | 17.48% | 16.31% | 13.30% | -8.42% |
D&A For EBITDA | 9.55 | 9.56 | 7.02 | 5.66 | 5.88 | 5.92 |
EBIT | 7.1 | 5.84 | 11.92 | 12.79 | 8.49 | -12.38 |
EBIT Margin | 6.87% | 5.87% | 11.00% | 11.31% | 7.85% | -16.13% |
Effective Tax Rate | - | - | - | 301.89% | - | - |